Safety of medical treatments for endometriosis

被引:54
作者
Berlanda, Nicola [1 ,3 ]
Somigliana, Edgardo [1 ,3 ]
Vigano, Paola [2 ]
Vercellini, Paolo [1 ,3 ]
机构
[1] Univ Milan, Osped Maggiore Policlin, Fdn CaGranda, Dept Obstet Gynecol, Milan, Italy
[2] Vita Salute Univ Milan, San Raffaele Sci Inst, Dept Obstet Gynecol, Milan, Italy
[3] Univ Milan, Milan, Italy
关键词
chronic pelvic pain; hormonal treatment of endometriosis; oral contraceptives; DEPOT-MEDROXYPROGESTERONE ACETATE; ORAL-CONTRACEPTIVE USE; BONE-MINERAL DENSITY; BREAST-CANCER RISK; VENOUS THROMBOEMBOLISM; POOLED ANALYSIS; POSTMENOPAUSAL ENDOMETRIOSIS; NORETHISTERONE ENANTHATE; PELVIC ENDOMETRIOSIS; INTRAUTERINE SYSTEM;
D O I
10.1517/14740338.2016.1121991
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Introduction: All medical treatments for endometriosis are equally effective in relieving pain. However, all of them alleviate pain symptoms for as long as they are used, but pain always relapses when medication is discontinued. Therefore, medications need to be used in the long term.Areas covered: Formulations of estro-progestins that contain less than 50 mu g of estrogen are associated with a low risk of venous thrombosis, myocardial infarction and stroke. When considering the neoplastic effects, data suggest that the overall risk of invasive cancer by age 60 is not increased in previous users of hormonal contraceptives. The use of progestins for contraception has never been associated with an increased risk of breast cancer, venous thromboembolism or bone fractures. Although more data on long-term therapy with progestins are needed, treatment of endometriosis with progestins may be feasible in women with metabolic or cardiovascular contraindications to estroprogestin. The other medications for the treatment of pain associated with endometriosis are less appropriate for long term administration because of side effects (danazol and GnRH analogues), costs (aromatase inhibitors and GnRH agonists) or necessity of complex regimens of associations (GnRH agonists and add back therapy or aromatase inhibitors plus progestins).Expert opinion: Progestins and estroprogestins are safe drugs to use in the long term. Adherence to these medications may be high because, being a contraceptive, they are perceived less as a medication for the treatment of a disease. The annual cost of therapy compares favorably with other available medications. Progestins and estroprogestins represent the first-line medications for the treatment of endometriosis associated pain.
引用
收藏
页码:21 / 30
页数:10
相关论文
共 81 条
[1]  
Akhter H, 1998, WHO TECH REP SER, V877, P1
[2]   Anastrazole and oral contraceptives: a novel treatment for endometriosis [J].
Amsterdam, LL ;
Gentry, W ;
Jobanputra, S ;
Wolf, M ;
Rubin, SD ;
Bulun, SE .
FERTILITY AND STERILITY, 2005, 84 (02) :300-304
[3]   Treatment of pelvic pain associated with endometriosis [J].
不详 .
FERTILITY AND STERILITY, 2008, 90 :S260-S269
[4]  
[Anonymous], COCHRANE DATABASE SY
[5]  
[Anonymous], COCHRANE DATABASE SY
[6]   GnRH analogs: Options for endometriosis-associated pain treatment [J].
Batzer, Frances R. .
JOURNAL OF MINIMALLY INVASIVE GYNECOLOGY, 2006, 13 (06) :539-545
[7]   Recent Oral Contraceptive Use by Formulation and Breast Cancer Risk among Women 20 to 49 Years of Age [J].
Beaber, Elisabeth F. ;
Buist, Diana S. M. ;
Barlow, William E. ;
Malone, Kathleen E. ;
Reed, Susan D. ;
Li, Christopher I. .
CANCER RESEARCH, 2014, 74 (15) :4078-4089
[8]   Oral Contraceptives and Breast Cancer Risk Overall and by Molecular Subtype Among Young Women [J].
Beaber, Elisabeth F. ;
Malone, Kathleen E. ;
Tang, Mei-Tzu Chen ;
Barlow, William E. ;
Porter, Peggy L. ;
Daling, Janet R. ;
Li, Christopher I. .
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2014, 23 (05) :755-764
[9]   Bone mineral density in adolescents using norethisterone enanthate, depot-medroxyprogesterone acetate or combined oral contraceptives for contraception [J].
Beksinska, Mags E. ;
Kleinschmidt, Immo ;
Smit, Jenni A. ;
Farley, Timothy M. M. .
CONTRACEPTION, 2007, 75 (06) :438-443
[10]   Bone mineral density in women aged 40-49 years using depot-medroxyprogesterone acetate, norethisterone enanthate or combined oral contraceptives for contraception [J].
Beksinska, ME ;
Smit, JA ;
Kleinschmidt, I ;
Farley, TMM ;
Mbatha, F .
CONTRACEPTION, 2005, 71 (03) :170-175